People: Anacor Pharmaceuticals Inc (ANAC.W)
ANAC.W on CBOE When Trading NASDAQ Global Select Market
5.48USD
23 May 2013
5.48USD
23 May 2013
Price Change (% chg)
$-0.02 (-0.36%)
$-0.02 (-0.36%)
Prev Close
$5.50
$5.50
Open
$5.53
$5.53
Day's High
$5.53
$5.53
Day's Low
$5.43
$5.43
Volume
3,300
3,300
Avg. Vol
2,132
2,132
52-wk High
$8.25
$8.25
52-wk Low
$3.05
$3.05
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Mark Leschly |
42 | Independent Chairman of the Board | |
David Perry |
43 | 2002 | President, Chief Executive Officer, Director |
Geoffrey Parker |
48 | 2010 | Chief Financial Officer, Senior Vice President |
Irwin Heyman |
69 | 2011 | Senior Vice President - Drug Development |
Kirk Maples |
52 | 2007 | Senior Vice President - Program Management |
Jacob Plattner |
64 | 2007 | Senior Vice President - Research |
Paul Berns |
45 | 2012 | Director |
Anders Hove |
46 | 2005 | Independent Director |
Paul Klingenstein |
57 | 2002 | Independent Director |
William Rieflin |
52 | 2011 | Independent Director |
Lucy Shapiro |
72 | 2000 | Independent Director |
Biographies
| Name | Description |
|---|---|
Mark Leschly |
Mr. Mark Leschly is the Independent Chairman of the Board of Anacor Pharmaceuticals Inc. He has served as a member of the Board since 2002. Since July 1999, Mr. Leschly has been a managing partner with Rho Capital Partners, Inc., an investment and venture capital management company. Previously, Mr. Leschly was an Associate and then a general partner of HealthCare Ventures, L.P., a venture capital management company, from 1994 through 1999. Mr. Leschly previously served as a director of Verenium Corporation, NitroMed, Inc., Senomyx, Inc. and Tercica, Inc., and he is on the board of a number of private companies. Mr. Leschly received an A.B. from Harvard University and an M.B.A. from the Stanford Graduate School of Business. |
David Perry |
Mr. David P. Perry is President and Chief Executive Officer and Director of Anacor Pharmaceuticals Inc. He has served as the President and Chief Executive Officer since March 2002 and has been a member of the Board since April 2002. In 1997, Mr. Perry founded Chemdex Corporation, a business-to-business marketplace company that focused on the life sciences industry, which was acquired by NexPrise Inc., and until 2001 served as its Chief Executive Officer. In 1995, Mr. Perry co-founded ViroGen, Inc., a biotech company based in Boston. Mr. Perry currently serves on the board of directors of the Infectious Disease Research Institute, a not-for-profit organization. Mr. Perry has a B.S. from the University of Tulsa and an M.B.A. from Harvard Business School. |
Geoffrey Parker |
Mr. Geoffrey M. Parker is Chief Financial Officer, Senior Vice President of Anacor Pharmaceuticals Inc. since September 2010. From December 2009 to September 2010, Mr. Parker provided consulting services to the company, including serving as Interim Chief Financial Officer from April 2010 to September 2010. From July 2009 to July 2010, Mr. Parker served in a consulting capacity as the Chief Business Officer of InteKrin Therapeutics, a privately held biopharmaceutical company in Los Altos, California. From 1997 to April 2009, Mr. Parker was a Vice President, then Managing Director and finally Partner at the global investment banking and securities firm Goldman Sachs Group, Inc., their West Coast Healthcare Investment Banking practice during this time. Mr. Parker also served in various capacities with Goldman Sachs Group, Inc. from 1990 to 1995 and 1986 to 1988. From 1995 to 1997, Mr. Parker was Vice President at Feibusch & Co., a venture capital firm in Larkspur, California. Mr. Parker is currently a member of the board of directors of ChemoCentryx, Inc., a clinical-stage privately held biopharmaceutical company. Mr. Parker received an A.B. from Dartmouth College in Engineering Sciences and Economics and an M.B.A. from Stanford Graduate School of Business. |
Irwin Heyman |
Dr. Irwin A. Heyman, Ph.D., is Senior Vice President - Drug Development of Anacor Pharmaceuticals Inc since March 2011, after serving as the company's Senior Vice President, Product Development from August 2008 to March 2011 and the company's Vice President, Toxicology from January 2006 to August 2008. From September 2003 to December 2005, Dr. Heyman was Executive Vice President, Drug Development, for KineMed, Inc., a pharmaceutical research and development company. From April 2001 to August 2003, Dr. Heyman served as the Chief Operating Officer of Biophiltre, Inc., a medical device company. From 1997 to 2001, he served as the Senior Vice President, Product Development for Pherin Pharmaceuticals, Inc. From 1985 to 1995, he held various positions of increasing responsibility with Syntex Corporation, a specialty pharmaceutical company, including Vice President, Institute of Pathology, Toxicology and Drug Metabolism, Vice President, Drug Evaluation, and Vice President, Preclinical Product Safety and Development. Prior to Syntex, Dr. Heyman also held various positions of increasing responsibility at Abbott Laboratories, a pharmaceutical company, including Director of Toxicology. Dr. Heyman received a B.S. from the University of Maryland, School of Pharmacy and a Ph.D. in pharmacology from the University of Maryland, School of Medicine. |
Kirk Maples |
Dr. Kirk R. Maples, Ph.D is Senior Vice President - Program Management of Anacor Pharmaceuticals Inc since January 2007, after serving as the company's Vice President, Preclinical Development from August 2002 to January 2007. From December 2001 to August 2002, Dr. Maples worked with Anacor as part of his responsibilities as a consultant to the Defense Advanced Research Projects Agency, or DARPA. Prior to joining DARPA as a consultant in 2001, Dr. Maples was Senior Vice President, Research of Centaur Pharmaceuticals, Inc., a pharmaceutical research and development company, where he served in senior management positions with research oversight since 1993. He was a Clinical Assistant Professor at the University of New Mexico College of Pharmacy from 1991 to 1993. Dr. Maples received a B.S. from the University of Missouri at Kansas City and a Ph.D. in inorganic chemistry from Duke University. |
Jacob Plattner |
Dr. Jacob J. Plattner, Ph.D. is Senior Vice President - Research of Anacor Pharmaceuticals Inc since January 2007, after serving as the company's Vice President, Research from February 2004 to January 2007. From 1998 to 2004, Dr. Plattner was Vice President of Small Molecule Discovery Research at Chiron Corporation, a biopharmaceutical company. Prior to joining Chiron, Dr. Plattner held managerial and research positions in chemistry and pharmaceutical research with Abbott Laboratories, a pharmaceutical company, from 1977 to 1998. Dr. Plattner received a B.S. from the University of Illinois and a Ph.D. in organic chemistry from the University of California, Berkeley. |
Paul Berns |
Mr. Paul L. Berns has been appointed as Director of Anacor Pharmaceuticals Inc., effective May 30, 2012. Prior to joining Allos Therapeutics, Mr. Berns was President, Chief Executive Officer and a director of Bone Care International, a specialty pharmaceutical company that was acquired by Genzyme Corporation in 2005. From 2001 to 2002, Mr. Berns served as Vice President and General Manager of the Immunology, Oncology and Pain Therapeutics business unit of Abbott Laboratories. From 2000 to 2001, he served as Vice President, Marketing of BASF Pharmaceuticals-Knoll, a pharmaceutical company, and from 1990 to 2000, Mr. Berns held various positions, including senior management roles, at Bristol-Myers Squibb Company. Mr. Berns serves on the Boards of Directors of XenoPort and Jazz Pharmaceuticals. Mr. Berns received a B.S. in Economics from the University of Wisconsin. |
Anders Hove |
Dr. Anders D. Hove, M.D., is Independent Director of Anacor Pharmaceuticals Inc since 2005. Dr. Hove is a general partner of Venrock Associates, a venture capital firm, which he joined in January 2004. From 1996 to 2004, Dr. Hove was a fund manager at BB Biotech Fund, an investment firm, and from 2002 to 2003 he also served as Chief Executive Officer of Bellevue Asset Management, LLC, an investment company. Dr. Hove is a member of the board of directors of World Heart Corporation, Alimera Sciences, Inc. and a number of private companies. He received an M.Sc. from the Technical University of Denmark, an M.D. from the University of Copenhagen and an M.B.A. from the Institut Européen d'Administration des Affaires, or INSEAD. |
Paul Klingenstein |
Mr. Paul H. Klingenstein is Independent Director of Anacor Pharmaceuticals Inc since 2002. He is the managing partner of Aberdare Ventures, a venture capital firm which he founded in 1999. Formerly, he was a partner of Accel Partners. Earlier he was an employee of Warburg Pincus and an advisor to the Rockefeller Foundation. Mr. Klingenstein is currently a director of EnteroMedics Inc. and several private companies. He is a former director of Aviron, Glycomed Inc., Isis Pharmaceuticals, Inc., Pharmion Corporation, Viagene, Inc., Xomed Inc., and several private companies and is Board Chairman of the International AIDS Vaccine Initiative. He received an A.B. from Harvard University and an M.B.A. from the Stanford Graduate School of Business. |
William Rieflin |
Mr. William J. Rieflin is Independent Director of Anacor Pharmaceuticals Inc. since March 2011. Since September 2010, he has been the Chief Executive Officer and a director of NGM Biopharmaceuticals, Inc., a biotechnology company. From 2004 until 2010, he served as President of XenoPort, Inc., a biotechnology company focused on the discovery and development of transported prodrugs. From 1996 to 2004, he held various positions with Tularik Inc., a biotechnology company focused on the discovery and development of product candidates based on the regulation of gene expression, the most recent of which was Executive Vice President, Administration, Chief Financial Officer, General Counsel and Secretary. Amgen Inc., a biotechnology company, acquired Tularik in 2004. Mr. Rieflin is currently a director of XenoPort, Inc. and NGM Biopharmaceuticals, Inc. Mr. Rieflin received a B.S. from Cornell University, an M.B.A. from the University of Chicago Graduate School of Business and a J.D. from Stanford Law School. |
Lucy Shapiro |
Dr. Lucy Shapiro, Ph.D., is Independent Director of Anacor Pharmaceuticals Inc since inception in 2000. She is also the co-chair of the scientific advisory board. Dr. Shapiro, the Virginia and D.K. Ludwig Professor of Cancer Research and Director of the Beckman Center for Molecular and Genetic Medicine in the School of Medicine at Stanford University, has been at Stanford University since 1989. Dr. Shapiro is a Fellow of the American Association for the Advancement of Sciences and has been elected to the National Academy of Sciences, the American Academy of Microbiology, the American Academy of Arts and Sciences and the Institute of Medicine of the National Academy of Sciences for her work in the fields of molecular biology and microbiology. She was elected to the American Philosophical Society and received the Selman Waksman Award from the National Academy of Sciences in 2005 and in 2009 was given the Gairdner International Award, considered one of the most prestigious awards in biomedical science. In 2010, she was presented with the Abbott Lifetime Achievement Award. Dr. Shapiro is currently a non-executive director of Gen-Probe, Inc., and she was a non-executive director of GSK from 2001 to 2006. She received a B.S. from Brooklyn College and a Ph.D. in molecular biology from the Albert Einstein School of Medicine. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Mark Leschly |
-- |
David Perry |
825,980 |
Geoffrey Parker |
1,070,080 |
Irwin Heyman |
386,579 |
Kirk Maples |
447,481 |
Jacob Plattner |
471,105 |
Paul Berns |
-- |
Anders Hove |
-- |
Paul Klingenstein |
-- |
William Rieflin |
-- |
Lucy Shapiro |
-- |
As Of 30 Dec 2010
Options Compensation
| Name | Options | Value |
|---|---|---|
Mark Leschly |
0 | 0 |
David Perry |
365,866 | 18,293 |
Geoffrey Parker |
0 | 0 |
Irwin Heyman |
0 | 0 |
Kirk Maples |
0 | 0 |
Jacob Plattner |
0 | 0 |
Paul Berns |
0 | 0 |
Anders Hove |
0 | 0 |
Paul Klingenstein |
0 | 0 |
William Rieflin |
0 | 0 |
Lucy Shapiro |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
SHAPIRO LUCILLE |
15,000 | $8.04 |
SHAPIRO LUCILLE |
10,000 | $7.98 |
SHAPIRO LUCILLE |
10,000 | $6.94 |
SHAPIRO LUCILLE |
10,000 | $6.88 |
PLATTNER JACOB J |
20,000 | $0.60 |
MAPLES KIRK R |
3,000 | $5.22 |
MAPLES KIRK R |
3,000 | $5.81 |
SHAPIRO LUCILLE |
15,000 | $6.66 |
SHAPIRO LUCILLE |
15,000 | $6.69 |
SHAPIRO LUCILLE |
14,400 | $6.54 |
SHAPIRO LUCILLE |
5,600 | $6.65 |
SHAPIRO LUCILLE |
10,000 | $6.58 |
SHAPIRO LUCILLE |
10,000 | $6.35 |
MAPLES KIRK R |
3,000 | $6.55 |
SHAPIRO LUCILLE |
10,000 | $6.30 |
VENROCK ASSOCIATES IV L P |
19,273 | $6.30 |
HOVE ANDERS D |
19,273 | $6.30 |
HOVE ANDERS D |
35,000 | $6.51 |
VENROCK ASSOCIATES IV L P |
35,000 | $6.51 |
VENROCK ASSOCIATES V L P |
35,000 | $6.51 |
VENROCK ASSOCIATES IV L P |
15,000 | $6.56 |
HOVE ANDERS D |
15,000 | $6.56 |
HOVE ANDERS D |
10,177 | $6.64 |
VENROCK ASSOCIATES IV L P |
10,177 | $6.64 |
MAPLES KIRK R |
3,000 | $6.17 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
